Abstract. The term ‘long non-coding RNAs’ (lncRNAs) refers to all non-protein coding transcripts >200 nucleotides in length. Dysregulation of lncRNAs has been identified in colorectal cancer, which is one of the more serious types of cancer worldwide, third place in the mortality rates, and is associated with poor prognoses. Novel evidence suggests that lncRNAs serve an important role in regulating the development and progression of colorectal cancer. In the present study, it was demonstrated that SNHG6 expression was downregulated in colorectal cancer tissues by reverse transcription quantitative polymerase chain reaction assays; however, ETS1 expression levels were upregulated. Overexpression of SNHG6 not only inhibited the proliferation of colon cancer cells in vitro by inducing apoptosis, but also inhibited cell proliferation, invasion and migration. The overexpression of SNHG6 inhibited colon cell viability and proliferation by targeting ETS1 through the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathway. These results suggested that SNHG6 may directly suppress ETS1, which may be one of potential mechanisms through which it inhibits the viability and proliferation of colorectal cancer cells, and it provides novel insight into the carcinogenesis of colorectal cancer. In addition, it may assist in the development of a treatment approach for ETS1-activated colorectal cancer.

Introduction

The incidence of colorectal cancer is increasing globally. A total of ~655,000 people succumb to colorectal cancer each year. The 5-year survival rate of early colorectal cancer is ~90%, but this rate decreases to 15% in metastatic colorectal cancer (1). Although numerous protocols for early screening and treatment have been developed in previous years, there has been no significant increase in the survival rate of colorectal cancer in the past 20 years (2). In addition, the most common cause of treatment failure is metastasis. This process is multifaceted, involving cancer cell invasion, epithelial mesenchymal transition (EMT), extracellular matrix degradation, angiogenesis and microenvironment chemotactic action. The abnormal activation or inactivation of a number of oncogenes or tumor suppressor genes and signaling pathways are regulated at transcriptional, post-transcriptional and translational levels, and the regulatory mechanisms are complex (3).

Colorectal cancer is one of the three most common fatal types of tumor, with up to 1.03 million cases each year and 530,000 mortalities each year in developed countries including Western Europe and the United States of America,. According to China's Ministry of Health, the incidence of colorectal cancer is the third-highest incidence of all cancers (4). Colorectal cancer is a malignant tumor caused by multiple factors, including individual genetics and environmental effects. For example, large-scale genetic studies have identified that the occurrence of colorectal cancer is associated with multiple genes abnormal expression and multiple molecular interactions (5-7), but the studies investigating the molecular mechanism of colorectal cancer incidence are not exhaustive. Therefore, additional studies exploring the pathogenesis of colorectal cancer may provide the theoretical basis for novel clinical anti-tumor drugs (8).

Long non-codingRNAs (lncRNA) are a type of molecule within the transcriptome in the cell nucleus or cytoplasm, similar to mRNA, with a length >200 nucleotides. Previous studies have demonstrated that lncRNA is closely associated with the occurrence of cancer (9,10). Abnormal lncRNAs may serve key roles as tumor suppressor genes or oncogenes. Colorectal cancer has one of the most rapidly increasing morbidity rates and has become a threat to health and life. (11).

Correspondence to: Dr Rui Zhang, Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 44 Wanquan Street, Dadong, Shenyang, Liaoning 110042, P.R. China
E-mail: zhangrui8798@126.com

Key words: small nucleolar RNA host gene 6, E26 transformation specific-1, colorectal cancer, phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway
Studies investigating this association between lncRNAs and cancer have indicated from non-small cell lung cancer genome-wide microarray data that small nuclear RNA host gene 6 (SNHG6), LINC00649, DLX6-AS1 and 3 lncRNA were identified to be abnormally expressed in patients with lung cancer (9-11), but no study has demonstrated whether lncRNA SNHG6 serves a significant role in colorectal cancer.

The normal human E26 transformation specific-1 (ETSI) gene is a proto-oncogene. It has been suggested that the ETS1 gene is involved in cell growth and extracellular matrix invasion, which promotes tumor invasion and metastasis (12). Previous studies have indicated that the expression of ETS1 is increased in a number of malignant tumors (12,13). The expression of ETS1 and its roles in tumor invasion and metastasis have attracted widespread attention.

The present study investigated the role of lncRNA SNHG6 in the development of colorectal cancer; the results identified that the expression of lncRNA SNHG6 was inhibited in tumor cells and tissues, and that the overexpression of lncRNA SNHG6 in cells may suppress ETS1 expression, inhibit cell proliferation. In addition, it was confirmed that the lncRNA SNHG6 inhibited ETS1 expression by directly targeting its 3'-untranslated regions (UTR) and activated the intrinsic invasion pathway through downregulating expression of phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR).

Materials and methods

Colorectal cancer tissue samples and the variant choice of SNHG6. A total of 30 colon tumors and adjacent non-tumor tissues samples were collected from patients with colorectal cancer from the Cancer Hospital of China Medical University (Shenyang, China) between April 2017 and September 2017. There were 18 males and 12 females; the age range was 34-82 years old, with a median age of 52 years. Patients were diagnosed according to the World Health Organization colon cancer histology classification and grading standards 2010 (14). The colon cancer staging system proposed by the American Cancer Association (AJCC) has become widely recognized as an independent indicator that can comprehensively reflect the progress of malignant tumors and judge prognosis (15). All patients with colon tumors enrolled in the present study did not receive any treatment prior to surgery. This was due to the fact that different radiotherapy or chemotherapy regimens may affect the outcomes of genetic studies of colon cancer, and it is difficult to standardize the frequency and intensity of different chemotherapy and radiotherapy treatments within the patient cohort. The protocol was approved by the ethics committee of cancer therapy and radiotherapy treatments within the patient cohort.

For transfection, cells at a density of 1x10^6 cells/well were seeded in each well of a 24-well microplate, grown for 24 h to reach 30-50% confluence and then incubated with 50 nM LncRNA pWPXL-SNHG6 and small interfering (si)-SNHG6 and si-negative control with lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) in 100 µl serum-free DMEM, according to the manufacturer's protocols.

RNA isolation and reverse transcription quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from SW480 and HCT-116 cell lines using TRIZol® (Thermo Fisher Scientific, Inc.). The corresponding RNA was reverse transcribed into cDNA using a QuantiFast SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany). Then, RT-qPCR analysis was detected using the SYBR Green qPCR Master Mix (5 µl; Invitrogen; Thermo Fisher Scientific, Inc.) on a 7500 Fast system (Applied Biosystems; Thermo Fisher Scientific, Inc.). For the PCR experiments, the following forward and reverse primers were used: SNHG6; Forward, 5'-TGc caG caG TGa Tc -3' and reverse, 5'-GGT GaG caT ccaT-3'; and reference gene GAPDH; Forward, 5'-CAGGAGGTTGAGGTG CGAT-3'; and reverse, 5'-GGTGGAGCAT TATCACCCGAA-3'.

The PCR conditions included an initial denaturation step of 94°C for 2 min, followed by 30 cycles of 94°C for 30 sec, 59°C for 30 sec, 72°C for 2 min and a final elongation step at 72°C for 10 min. Taq DNA polymerase was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). GAPDH was used as an internal control to normalize gene expression. The relative gene expression levels were calculated using the ΔΔCq method (17).

Western blot analysis. Protein samples from cells were homogenized using radioimmunoprecipitation assay lysis buffer (Invitrogen; Thermo Fisher Scientific, Inc.). The protein concentrations of the cell extracts were then measured using Bradford protein dye reagent (Bio-rad laboratories, Inc., Hercules, CA, USA). A total of 30 µg/lane protein was loaded. The proteins lysates were separated on a 10% SDS-PAGE separation gel and transferred onto a nitrocellulose membrane by 300 mA for 90 mins, blocked with 5% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.) for 2 h at room temperature, and incubated with primary antibodies (Abcam, UK): anti-ETSI (1:2,000; ab26096), anti-p-PI3K (1:2,000; ab151549), anti-PI3K (1:2,000; ab32089) anti-p-AKT (1:3,000; ab8932), anti-AKT (1:2,000; ab38449), anti-p-mTOR (1:2,000; ab109268), anti-mTOR (1:2,000; ab2732) and anti-GAPDH (1:1,000; ab9485) at 4°C overnight. Then, membranes were incubated at room temperature for 2 h with anti-IgG conjugated with horseradish peroxidase secondary antibodies (1:5,000; ab97040) before being visualized using the SuperSignal West Pico Chemiluminescent Substrate Trial kit (Pierce Protein
Biology; Thermo Fisher Scientific, Inc.). Images were obtained using the ChemiDoc XRS system with Quantity One software (Bio-Rad Laboratories, Inc.). Protein expression was analyzed using BandScan 5.0 software (Glyko, Inc., Novato, CA, USA). All experiments were repeated three times.

Cell proliferation analysis. Cells proliferation was detected in vitro using an MTT assay. Briefly, following transfection, HCT-116 cell lines were seeded at a density of 2,000 cells/well in 96-well plates and all groups were incubated for 24, 48, 72 or 96 h. MTT was added into each well (5 mg/ml; Sigma-Aldrich; Merck KGaA), and culture was maintained at 37°C for 4-6 h. Samples were measured at 570 nm using the MTT cell proliferation kit (Cayman Chemical Company, Ann Arbor, MI, USA).

Flow cytometry. For the cell apoptosis analysis, HCT116 cells were harvested 48 h after transfection and immobilized in 70% ethanol at -20°C for 30 min. Then, the cells were resuspended in 10 ml RNase, and stained with propidium iodide (PI; 1:200) and Annexin V-FITC (1:200; BD Pharmingen, San Diego, CA, USA) for 30 min at 37°C. A total of 500 µl PBS was added and mixed thoroughly. The samples were then analyzed by a FACScan flow cytometer (BD Biosciences). Apoptotic rate of cells was analyzed by flow cytometry (BD, Biosciences) using WinMDI software (version 2.9; BD Biosciences). All experiments were repeated 3 times.

Transwell invasion assays. The pore size in the bottom membrane of the Transwell chambers (Corning Incorporated, Corning, NY, USA) was 8 µm. The chambers were coated with Matrigel (Sigma-Aldrich; Merck KGaA) for the determination of cell invasive abilities at room temperature for 24 h. HCT116 cells were grown to ~80% confluence in the 24-well Transwell plates. Then, after 24 h incubation at 37°C in 15% fetal bovine serum medium, the invasion of cells was measured using light microscopy at a magnification of x200 (Shanghai Bime Instrument Co., Ltd., Shanghai, China).

Cell scratch assay. HCT116 cells (5x10⁴ cells/well) were seeded in a 6-well plate (5x10⁴ cells per well). Lines were then drawn behind the plate with a ruler. Following attachment of the cells, a scratch was made across the middle of the wells, the width of a 10 µl pipette tip. Non-adherent cells were removed by washing with PBS 3 times, and then serum-free medium (Gibco; Thermo Fisher Scientific, Inc.) was added. Cells were incubated at 37°C and 5% CO₂. Images were captured at 0 and 48 h.

Statistical analysis. Data are presented as the mean ± standard deviation of 3 independent experiments. The results were analyzed using a Student t-test or a one-way analysis of variance with Tukey's post-hoc test. All the data were analyzed using SPSS Statistics 19.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) with Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

LncRNA SNHG6 is downregulated in colon cancer tissues and cell lines. A previous study demonstrated that SNHG6
MenG et al.: SnHG6 inhibits CRC by targeting ETS1 via PI3K/AKT/MTOR

The expression of lncRNA SnHG6 has not been determined in colon cancer. Firstly, the expression of lncRNA SnHG6 was detected in 30 pairs of colon cancer and adjacent tissues by RT-qPCR. The RT-qPCR results verified that the expression of lncRNA SnHG6 was markedly decreased in colon cancer tissues compared with the normal tissues (Fig. 1A). Furthermore, similar results were observed when examining colon cancer cell lines, in which the expression of lncRNA SnHG6 was markedly decreased compared with the normal colon cell line (Fig. 1B). In addition, the expression of ETS1, which is a transcription factor, was detected. The western blot analysis results suggested that ETS1 was highest in colon cancer cell lines (Fig. 1C). These data indicate that lncRNA SnHG6 may serve a key role in colon cancer progression.

**LncRNA SNHG6 represses colon cancer proliferation.**

To additionally explore the role of lncRNA SNHG6 in colon cancer cells, the cell proliferation rates were detected in vitro following transfection with pWPXL-SNHG6 plasmids and si-SNHG6 to overexpress or silence lncRNA SNHG6 expression, respectively. The transfection efficiency was detected by RT-qPCR. The RT-qPCR results demonstrated that lncRNA SNHG6 expression was effectively upregulated following transfection with pWPXL-SNHG6; conversely, lncRNA SNHG6 expression was markedly decreased in cells following transfection with si-SNHG6 (Fig. 2A). Furthermore, an MTT assay was used to detect the proliferation of colon cancer cells. As demonstrated in Fig. 2B, the proliferation of colon cancer cells was significantly inhibited following overexpression of lncRNA SNHG6, whereas inhibition of lncRNA SNHG6 significantly increased levels of cell growth. The western blot analysis results suggested that the levels of ETS1 were downregulated when transfected with pWPXL-SNHG6 and upregulated when transfected with si-SNHG6 (Fig. 2C). In conclusion, lncRNA SNHG6 inhibited the proliferation of colon cancer cells.

**LncRNA SNHG6 inhibits proliferation and induces apoptosis of colon cancer cells.**

Flow cytometry was used to detect the expression of the Annexin V and PI. As indicated in Fig. 3A, the apoptosis levels were identified to be increased when lncRNA SNHG6 was overexpressed in colon cells, and...
LncRNA SNHG6 inhibits migration of colon cancer cells. Cell scratch assays were used to detect the migration of colon cancer cells. Overexpression of lncRNA SNHG6 in HCT116 cells caused a decrease in cell migration levels, while transfection with si-SNHG6 resulted in an increase in the levels of migration in colon cancer cells (Fig. 4A and B).

LncRNA SNHG6 regulates cell proliferation through the PI3K/AKT/mTOR signaling pathway. Previous data have demonstrated that the PI3K/AKT/mTOR signaling pathway promotes the development and progression of colon cancer (18,19). Therefore, the protein expression levels of phosphorylated-PI3K (p-PI3K), p-AKT, p-mTOR, PI3K, AKT and mTOR were detected by western blot analysis. The results demonstrated that the p-AKT, p-PI3K and p-mTOR expression levels were markedly decreased following overexpression of lncRNA SNHG6 (Fig. 5A and B). These results suggest that lncRNA SNHG6 regulates cell proliferation through the PI3K/AKT/mTOR signaling pathway in colon cancer.

Discussion
Colon cancer is one of the most common malignant tumors in clinical practice, and its morbidity and mortality rates are increasing in the majority of countries and regions throughout the world, which poses a serious threat to human health. The primary causes of mortality in these patients are invasion, metastasis and chemotherapy resistance. The mechanism of metastasis of colon cancer is complicated, and involves the abnormal expression of multiple oncogenes and tumor suppressor genes; previous studies have identified that abnormal lncRNA expression is also an important factor (9-11). Mature lncRNA may be located in the mRNA noncoding regions (3'-UTR or introns area) of their target gene, and may result in complete or incomplete complementary pairing, degradation.
or inhibition of mRNA translation and post-transcriptional alterations in gene expression. They may also participate in the regulation of cell differentiation, proliferation, apoptosis, and tissue and organ development (5,7,17).

Previous studies have confirmed that lncRNA may regulate the expression of at least 30% of human protein-coding genes (18), and serve a larger role compared with protein-coding genes (19,20). In a variety of human tumors, abnormal expression of lncRNA is caused by gene mutation at brittle gene sites during gene transfer activation (21). More recent studies have identified that SNHG6 promoted growth of nasopharyngeal tumors through targeted regulation of lactotransferrin, and affected glioma cell aging through regulation of cytoplasmic polyadenylation element binding protein 1 gene expression (7,22). These data suggest that lncRNA SnHG6 is closely associated with the occurrence of tumor development.

The downregulation of lncRNA SNHG6 has been associated with a variety of tumors: The expression of lncRNA SNHG6 in breast cancer cells was revealed to inhibit the growth of bone metastasis and lung metastasis in situ tumors, and the survival rate of patients with low expression of lncRNA SNHG6 was significantly decreased compared with that of the high expression group (22). Previous studies have also demonstrated that lncRNA SNHG6 was significantly downregulated in gastric cancer tissues compared with normal tissues, and increased lncRNA SNHG6 may significantly induce cell cycle arrest and inhibition in gastric cancer cells, and inhibit the invasion ability of gastric cancer cells and the ability of tumor and metastasis in vivo (9,23). In addition, other studies have also suggested that lncRNA SNHG6 may inhibit the invasion ability of lung cancer cells (9-11). However, the function and potential mechanism of action of lncRNA SNHG6 in colon cancer remains to be elucidated, in particular how SNHG6 affects cell migratory and invasive capabilities. At present, with the development of sequencing technologies and the progression of investigative studies, a number of lncRNAs have been identified and investigated. It has been demonstrated that SNHG6 affected the migration and invasion of cancer cells by altering the expression of...
epithelial mesenchymal transition; this involves the participation of multiple signaling pathways (9). The present study initially explored the association between SNHG6 and PI3K/AKT/mTOR signaling pathways.

A previous study hypothesized that SNHG6 represented an unusual snoRNA gene, and there is a difference in the pathogenesis of malignant tumors and that the knowledge base concerning IncRNA was underdeveloped (24). In the present study, knockdown and overexpression of SNHG6 was achieved, and qPCR used to detect the expression level of SNHG6. Due to the limitations of the experimental conditions in the present study including technology and funding, the localization of IncRNA SNHG6 was not examined.

In the present study, the role of IncRNA SNHG6 in the development of colorectal cancer was investigated; it was identified that the expression of IncRNA SNHG6 was inhibited in tumor cells and tissues, and that the overexpression of IncRNA SNHG6 in cells suppressed ETS1 expression, inhibited cell proliferation. In addition, it was confirmed that the IncRNA SNHG6 inhibited ETS1 expression by directly targeting its 3'-UTR and activating the intrinsic invasion pathway through downregulating the expression of PI3K/AKT/mTOR. Therefore, IncRNA SNHG6 may be a novel therapeutic target for colon cancer. The results also suggested that this suppression of ETS1 may a potential mechanism of SNHG6-mediated inhibition of the viability, proliferation and migration of colorectal cancer cells, and they provide novel insights into the carcinogenesis of colorectal cancer. To characterize the association between ETS1 and SNHG6 in greater detail, correlation between sequences determined by complementarity between sequence bases studies and luciferase tests are required. In addition, it may be useful for the development of a treatment approach for ETS1-activated colorectal cancer. The present study demonstrated that IncRNA SNHG6 inhibited cell proliferation and metastasis by targeting ETS1, and established preliminary associations with the PI3K/AKT/mTOR signaling pathways; future studies investigating the specific mechanisms are required.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Fund from the National Natural Science Foundation of China (grant no. 81672427).

Availability of data and materials
The datasets generated and analyzed during the present study are not publicly available due to further research being performed, but are available from the corresponding author on reasonable request.

Authors' contributions
SM and ZJ designed the study. XY, and JL performed the experiments. RZ analyzed the data.

Ethics approval and consent to participate
The protocol was approved by the Ethics Committee of Cancer Hospital of China Medical University, and written informed consent was obtained from all study participants.

Patient consent for publication
Written informed consent was obtained from all study participants.

Competing interests
The authors declare that they have no competing interests.

References
1. Jones P, Cade JE, Evans CEL, Hancock N and Greenwood DC: Does adherence to the World Cancer Research Fund/American Institute of Cancer Research cancer prevention guidelines reduce risk of colorectal cancer in the UK Women's cohort study? Br J Nutr 119: 340-348, 2018.
2. van der Werf A, Arthely K, Hiesmayr M, Sulz I, Schindler K, Laviano A, Langius J and de van der Schueren M: The determinants of reduced dietary intake in hospitalised colorectal cancer patients. Support Care Cancer 26: 2029-2047, 2018.
3. Han J, Hur H, Min BS, Lee KY and Kim n K: Predictive factors for lymph node metastasis in submucosal invasive colorectal carcinoma: A new proposal of depth of invasion for radical surgery. World J Surg 42: 2635-2641, 2018.
4. Souza BU, Souza NCS, Martucci RB, Rodrigues DV, Pinho NB, Gonzalez MC and Avesani CM: Factors associated with sarcopenia in patients with colorectal cancer. Nutr Cancer 70: 176-183, 2018.
5. Woodall M and DeLette M: Colorectal cancer: A collaborative approach to improve education and screening in a rural population. Clin J Oncol Nurs 22: 69-75, 2018.
6. Ruiz-Tovar J, Liavero C, Morales V and Gamallo C: Effect of the application of a bundle of three measures (intraperitoneal lavage with antibiotic solution, fascial closure with triclosan-coated sutures and mupirocin ointment application on the skin staples) on the surgical site infection after elective laparoscopic colorectal cancer surgery. Surg Endosc 32: 3495-3501, 2018.
7. Wu W, Yan S, Liao X, Xiao H, Fu Z, Chen L, Mou J, Yu H, Zhao L and Liu X: Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: A systematic review and meta-analysis. Oncotarget 8: 113202-113212, 2017.
8. Vayrynen JP, Tuomisto A, Vayrynen SA, Klintrup K, Karhu T, Mäkelä J, Herzig KH, Karttunen TJ and Mäkinen MJ: Preoperative anemia in colorectal cancer: Relationships with tumor characteristics, systemic inflammation, and survival. Sci Rep 8: 1126, 2018.
9. Yan K, Tian J, Shi W, Xia H and Zhu Y: LncRNA SNHG6 is associated with poor prognosis of gastric cancer and promotes cell proliferation and EMT through epigenetically silencing p27 and sponging miR-101-3p. Cell Physiol Biochem 42: 999-1012, 2017.
10. Birgani MT, Hajari M, Shahriasa A, Khoshnevisan A, Shoja Z, Motahari P and Farhangi B: long non-coding RNA SNHG6 is a potential biomarker for hepatocellular carcinoma. Pathol Oncol Res 24: 329-337, 2017.
11. Cao C, Zhang T, Zhang D, Xie L, Zou X, Lei L, Wu D and Liu L: The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene 36: 1112-1122, 2017.
12. Cao B, Tan S, Tang H, Chen Y and Shu P: miR3125p suppresses proliferation, migration and invasion, and induces apoptosis in nonsmall cell lung cancer cells by targeting ETS1. Mol Med Rep 19: 3604-3614, 2019.
13. Conrad S, Demurger F, Moradkhani K, Pichon O, Le Caigec C, Duclos C, Thomas C, Bayart S, Perlat A, Dubourg C, et al: 11q24.2q24.3 microdeletion in two families presenting features of Jacobsen syndrome, without intellectual disability: Role of FL11, ETS1, and SENCR long noncoding RNA. Am J Med Genet A 179:993-1000, 2019.
14. Shen C, Yin Y, Chen H, Tang S, Yin X, Zhou Z, Zhang B and Chen Z: Neuroendocrine tumors of colon and rectum: Validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European neuroendocrine tumor society staging systems. Oncotarget 8: 22123-22134, 2017.

15. Expert Panel on Gastrointestinal Imaging, Fowler KJ, Kaur H, Cash BD, Feig BW, Gage KL, Garcia EM, Hara AK, Herman JM, Kim DH, et al: ACR appropriateness criteria(R): pretreatment staging of colorectal cancer. J Am Coll Radiol 14: S234-S244, 2017.

16. Ogawa T, Hirohashi Y, Murai A, Nishidate T, Okita K, Wang L, Ikehara Y, Satoyoshi T, Usui A, Kubo T, et al: ST6GalNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway. Oncotarget 8: 112550-112564, 2017.

17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

18. Luan A, Hu MS, Leavitt T, Brett EA, Wang KC, Longaker MT and Wan DC: Noncoding RNAs in Wound Healing: A new and vast frontier. Adv Wound Care (New Rochelle) 7: 19-27, 2018.

19. Sallam T, Sandhu J and Tontonoz P: Long noncoding RNA discovery in cardiovascular disease: Decoding form to function. Circ Res 122: 155-166, 2018.

20. Chen S, Zhu J, Wang F, Guan Z, Ge Y, Yang X and Cai J: LncRNAs and their role in cancer stem cells. Oncotarget 8: 110685-110692, 2017.

21. Malhotra A, Jain M, Prakash H, Vasquez KM and Jain A: The regulatory roles of long non-coding RNAs in the development of chemotherapy resistance in breast cancer. Oncotarget 8: 110671-110684, 2017.

22. Lv P, Qiu X, Gu Y, Yang X, Xu X and Yang Y: Long non-coding RNA SNHG6 enhances cell proliferation, migration and invasion by regulating miR-26a-5p/MAPK6 in breast cancer. Biomed Pharmacother 110: 294-301, 2019.

23. Li Y, Li D, Zhao M, Huang S, Zhang Q, Lin H, Wang W, Li K, Li Z, Huang W, et al: Long noncoding RNA SNHG6 regulates p21 expression via activation of the JNK pathway and regulation of EZH2 in gastric cancer cells. Life Sci 208: 295-304, 2018.

24. Zhang Y, Li R, Ding X, Zhang K and Qin W: Upregulation of long non-coding RNA SNHG6 promotes esophageal squamous cell carcinoma cell malignancy and its diagnostic value. Am J Transl Res 11: 1084-1091, 2019.